Initial patient data
. | No. . |
---|---|
Number of patients | 103 |
Median age, y (range) | 6.8 (0.2-17.1) |
Sex, male/female | 54/49 |
Median WBC, 109/L (range) | 48 (2-688) |
Median percentage of leukemic cells, WBC (range) | 83 (1-100)* |
BCR/ABL, yes/no/NA | 1/44/58 |
MLL/AF4, yes/no/NA | 0/45/58 |
TEL/AML 1, yes/no/NA | 4/41/58 |
Liver, more than 3 cm below costal margin, yes/no/NA | 52/48/3 |
Spleen, more than 3 cm below costal margin, yes/no/NA | 51/49/3 |
Response to prednisone, good† poor‡ NA | 44/9/50 |
Immunophenotype | |
Precursor B lineage, male/female | 71 (34/37) |
T lineage, male/female | 32 (20/12) |
. | No. . |
---|---|
Number of patients | 103 |
Median age, y (range) | 6.8 (0.2-17.1) |
Sex, male/female | 54/49 |
Median WBC, 109/L (range) | 48 (2-688) |
Median percentage of leukemic cells, WBC (range) | 83 (1-100)* |
BCR/ABL, yes/no/NA | 1/44/58 |
MLL/AF4, yes/no/NA | 0/45/58 |
TEL/AML 1, yes/no/NA | 4/41/58 |
Liver, more than 3 cm below costal margin, yes/no/NA | 52/48/3 |
Spleen, more than 3 cm below costal margin, yes/no/NA | 51/49/3 |
Response to prednisone, good† poor‡ NA | 44/9/50 |
Immunophenotype | |
Precursor B lineage, male/female | 71 (34/37) |
T lineage, male/female | 32 (20/12) |